Impact of SGLT2 Inhibitors on Preventing Heart Failure Hospitalizations in Colombian Patients With Uncontrolled Type 2 Diabetes Mellitus.
SGLT2 抑制劑對於預防哥倫比亞未控制型 2 糖尿病患者心衰竭住院的影響。
Cureus 2025-02-20
The Impact of SGLT2 Inhibitors on Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction.
SGLT2 抑制劑對心臟收縮功能保留型心衰患者心血管結果的影響。
Ann Pharmacother 2024-04-12
Eligibility of sodium-glucose cotransporter-2 inhibitors in heart failure with preserved ejection fraction: Insights from the Colombian heart failure registry (RECOLFACA).
心臟衰竭伴保留射血分數的鈉-葡萄糖共轉運蛋白-2 抑制劑的適用性:來自哥倫比亞心臟衰竭登記(RECOLFACA)的見解。
Int J Cardiol Heart Vasc 2024-07-19
Sodium-glucose cotransporter 2 inhibitors reduce the risk of incident type 2 diabetes in people with heart failure without diabetes: An analysis of real-world, cohort data.
鈉-葡萄糖共轉運蛋白 2 抑制劑降低心衰竭無糖尿病患者發生 2 型糖尿病的風險:一項真實世界隊列數據的分析。
Diabetes Obes Metab 2024-08-07
Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Heart Failure in Patients With Type 2 Diabetes Mellitus: A Systematic Review.
鈉-葡萄糖共轉運蛋白-2 抑制劑對於2型糖尿病患者心臟衰竭的影響:系統性回顧。
Cureus 2024-10-04
Empagliflozin and other SGLT2 inhibitors in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis.
心衰竭且射血分數保留患者中 Empagliflozin 及其他 SGLT2 抑制劑的系統性回顧與統合分析。
Ther Adv Cardiovasc Dis 2024-10-14
Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study.
Empagliflozin 使用與北歐 2 型糖尿病患者的全因死亡率、心衰住院及末期腎病風險降低相關:來自 EMPRISE (Empagliflozin Comparative Effectiveness and Safety) 研究的結果。
J Diabetes Res 2024-10-21
Meta-analysis of the efficacy and impact on cardiac function of sodium-glucose cotransporter 2 inhibitor Empagliflozin in heart failure patients.
心衰竭患者中鈉-葡萄糖共轉運蛋白 2 抑制劑 Empagliflozin 的療效及對心臟功能影響的統合分析。
Medicine (Baltimore) 2024-11-13
Real-Life Individual Comparison of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Heart Failure and Diabetes Mellitus.
心衰竭及糖尿病患者中鈉-葡萄糖共轉運蛋白-2 抑制劑的實際個體比較。
Am J Cardiovasc Drugs 2024-11-28
Can SGLT-2 inhibitors improve cardiovascular outcomes and ensure safety for patients with type 2 diabetes and heart failure in Thailand? A real-world multicentre retrospective cohort study.
SGLT-2 抑制劑能否改善泰國 2 型糖尿病及心衰竭患者的心血管結果並確保安全性?一項真實世界多中心回顧性隊列研究。
BMJ Open 2024-12-13
Protective Influence of SGLT-2 Inhibitors Against Heart Failure in Type 2 Diabetes Mellitus Through Longitudinal Clinical Database Analysis.
SGLT-2 抑制劑對於 2 型糖尿病心衰竭的保護影響:透過縱向臨床資料庫分析。
J Clin Med 2024-12-17